Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plerixafor + G-CSF for stem cell mobilization in multiple myeloma
NCT05087212Phase 4Completed
- Sponsor
- Sanofi
- Start
- Oct 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of plerixafor, sponsored by Sanofi. Primary endpoint: Proportion of patients collecting ≥6×10^6 CD34+ cells/kg in 2 or fewer apheresis days at Day 6. Started Oct 2021; status: completed.
02
Drugs
plerixafor
Beyond the preview
Go deeper on NCT05087212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05087212.